Senti Biosciences (SNTI) Appoints Fran Schulz to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks weigh on markets
- Oil jumps around 5% to two-week high after Trump warns of more attacks on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Senti Biosciences, Inc. (SNTI) PT Raised to $12 at Chardan Capital Markets
December 4, 2024 6:54 AM ESTChardan Capital Markets analyst Geulah Livshits raised the price target on Senti Biosciences, Inc. (NASDAQ: SNTI) to $12.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "On 3 December, Senti Biosciences hosted a call to discuss initial data from the phase I trial of its... More
